Remix Therapeutics Unveils Phase 1 Data of REM-422 at Conference
Exciting Developments from Remix Therapeutics
WATERTOWN, Mass. — Remix Therapeutics, a pioneering clinical-stage biotechnology enterprise, is revolutionizing the world of RNA processing with its innovative therapies. This week, the company unveiled significant data from its Phase 1 clinical trial for the MYB RNA degrader, REM-422. The findings were accepted for a prominent late-breaking oral presentation during a major cancer therapeutic conference.
Presentation Highlights
The forthcoming presentation will showcase the trial's primary goals, which involve establishing the safety of REM-422, identifying dose-limiting toxicities, and determining a recommended phase 2 dose (RP2D). The study also aims to evaluate the preliminary anti-tumor effects of REM-422 on patients diagnosed with recurrent or metastatic adenoid cystic carcinoma (ACC).
Oral Presentation Details
Details regarding the oral presentation include the following:
- Title: A Phase I Trial of the MYB RNA degrader REM-422
- Presenter: Dr. Glenn J. Hanna from Dana-Farber Cancer Institute
- Date & Time: October 24; Plenary Session 4 from 10:00 - 11:40 am
- Location: Level 3, Ballroom AB
Poster Presentation Details
In addition to the oral presentation, there will be a poster session as follows:
- Title: A Phase I Trial of the MYB RNA degrader REM-422
- Presenter: Dr. Glenn Hanna
- Session and Poster Number: Poster Session B, LB-B005
- Date and Time: October 24 from 12:30 - 4:00 pm
- Location: Level 2, Exhibit Hall D
Participating in the RNA Targeting Session
In addition to their presentations, Remix Therapeutics will host a session focused on targeting RNA with small molecules. This session aims to gather leading experts and provide a platform for discussing innovative approaches in oncology.
Session Details
Here are the details of the concurrent session:
- Title: Concurrent Session 9: Targeting RNA with Small Molecules
- Co-Chair: Dr. Chris Bowden, Chief Medical Officer, Remix Therapeutics
- Presenter: Dr. Charles Kung, Vice President of Biology, Remix Therapeutics
- Featured Topic: REM-422, a first-in-class mRNA degrader of the MYB oncogene
- Date & Time: October 25 from 4:15 – 5:55 pm
- Location: Level C, Ballroom 3
About REM-422
REM-422 is an innovative oral small molecule classified as a first/best-in-class therapy. Its mechanism induces degradation of MYB mRNA, reducing protein expression through a sophisticated process that incorporates poison exons into the MYB mRNA transcript. This process results in the targeted decay of the unwanted transcript. Currently, REM-422 is being evaluated in Phase 1 clinical trials for ACC, Acute Myeloid Leukemia (AML), and high-risk myelodysplastic syndrome (HR-MDS). The U.S Food and Drug Administration has granted Orphan Drug Designation for both ACC and AML.
About Remix Therapeutics
Founded with a vision for reprogramming RNA processing, Remix Therapeutics is at the forefront of developing novel small molecule therapies. Their REMaster™ technology platform applies advanced data science and biomolecular methodologies to yield orally administered compounds that modulate gene expression. This innovative approach has led to the formulation of REM-422, now being explored in clinical studies for its potential against critical oncological diseases such as AML, HR-MDS, and ACC.
Contact Information
Media Contact:
Lisa Buffington
Buffington Comms
lbuffington@remixtx.com
Investor Contact:
Will O'Connor
Precision AQ
Will.OConnor@precisionaq.com
Frequently Asked Questions
What is REM-422?
REM-422 is a first-in-class, oral small molecule mRNA degrader developed by Remix Therapeutics designed to reduce MYB mRNA and protein expression.
What are the primary objectives of the Phase 1 trial?
The trial aims to determine the safety profile, any dose-limiting toxicities, and to define a recommended phase 2 dose (RP2D).
Who is the presenter at the oral session?
Dr. Glenn J. Hanna from the Dana-Farber Cancer Institute will present the findings.
What diseases is REM-422 targeting?
REM-422 is being investigated for its efficacy in treating recurrent or metastatic adenoid cystic carcinoma (ACC) and other critical cancers like Acute Myeloid Leukemia (AML).
Is REM-422 a new type of therapy?
Yes, it is considered a first/best-in-class therapy focused on modulating RNA processes to target the underlying drivers of disease.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
